MX347359B - Derivados de pirazolo-triazina como inhibidores selectivos de cinasas dependientes de ciclina. - Google Patents

Derivados de pirazolo-triazina como inhibidores selectivos de cinasas dependientes de ciclina.

Info

Publication number
MX347359B
MX347359B MX2014010494A MX2014010494A MX347359B MX 347359 B MX347359 B MX 347359B MX 2014010494 A MX2014010494 A MX 2014010494A MX 2014010494 A MX2014010494 A MX 2014010494A MX 347359 B MX347359 B MX 347359B
Authority
MX
Mexico
Prior art keywords
pyrazolo
triazine derivatives
diseases
inhinitors
dependent kinase
Prior art date
Application number
MX2014010494A
Other languages
English (en)
Spanish (es)
Other versions
MX2014010494A (es
Inventor
Eickhoff Jan
Zischinsky Gunther
Koch Uwe
Original Assignee
Lead Discovery Center Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lead Discovery Center Gmbh filed Critical Lead Discovery Center Gmbh
Publication of MX2014010494A publication Critical patent/MX2014010494A/es
Publication of MX347359B publication Critical patent/MX347359B/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10Spiro-condensed systems
    • C07D491/107Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/14Drugs for dermatological disorders for baldness or alopecia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • AIDS & HIV (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Molecular Biology (AREA)
MX2014010494A 2012-03-01 2013-03-01 Derivados de pirazolo-triazina como inhibidores selectivos de cinasas dependientes de ciclina. MX347359B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12157751.4A EP2634190A1 (en) 2012-03-01 2012-03-01 Pyrazolo-triazine derivatives as selective cyclin-dependent kinase inhinitors
PCT/EP2013/054224 WO2013128028A1 (en) 2012-03-01 2013-03-01 Pyrazolo - triazine derivatives as selective cyclin- dependent kinase inhinitors

Publications (2)

Publication Number Publication Date
MX2014010494A MX2014010494A (es) 2015-04-08
MX347359B true MX347359B (es) 2017-04-06

Family

ID=47757629

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014010494A MX347359B (es) 2012-03-01 2013-03-01 Derivados de pirazolo-triazina como inhibidores selectivos de cinasas dependientes de ciclina.

Country Status (17)

Country Link
US (1) US9567345B2 (enExample)
EP (2) EP2634190A1 (enExample)
JP (1) JP6182549B2 (enExample)
KR (1) KR101821452B1 (enExample)
CN (1) CN104350054B (enExample)
AU (1) AU2013224848B2 (enExample)
BR (1) BR112014021189B1 (enExample)
CA (1) CA2865946C (enExample)
DK (1) DK2820020T3 (enExample)
ES (1) ES2583231T3 (enExample)
HU (1) HUE029264T2 (enExample)
IL (1) IL234183A (enExample)
MX (1) MX347359B (enExample)
RU (1) RU2645347C2 (enExample)
SG (1) SG11201405129RA (enExample)
WO (1) WO2013128028A1 (enExample)
ZA (1) ZA201406078B (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA119247C2 (uk) 2013-09-06 2019-05-27 РОЙВЕНТ САЙЕНСИЗ ҐмбГ Спіроциклічні сполуки як інгібітори триптофангідроксилази
GB201403093D0 (en) 2014-02-21 2014-04-09 Cancer Rec Tech Ltd Therapeutic compounds and their use
CN110229142A (zh) 2014-04-04 2019-09-13 希洛斯医药品股份有限公司 细胞周期蛋白依赖性激酶7(cdk7)的抑制剂
EP3129371B1 (en) * 2014-04-05 2020-07-29 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
CA2966164C (en) 2014-10-31 2023-10-17 Ube Industries, Ltd. Substituted dihydropyrrolopyrazole compound
ES2899196T3 (es) * 2015-03-09 2022-03-10 Aurigene Discovery Tech Ltd Derivados de pirazolo[1,5-a][1,3,5]triazina y de pirazolo[1,5-a]pirimidina como inhibidores de CDK
MX394157B (es) 2015-06-15 2025-03-24 Ube Corp Derivado de dihidropirrolopirazol sustituido.
AU2016284638B2 (en) * 2015-06-24 2020-01-23 Curovir Ab Pyrazolo[1,5-a]triazin-4-amine derivatives useful in therapy
KR102480965B1 (ko) 2016-09-13 2022-12-26 알레간 인코포레이티드 안정화된 비단백질 클로스트리듐 독소 조성물
CN106432249B (zh) * 2016-09-30 2018-12-04 陕西科技大学 一类吡咯并[2,1-f][1,2,4]三嗪母核化合物的合成及其医药用途
EP3664806B1 (en) 2017-08-09 2025-04-30 Sanford Burnham Prebys Medical Discovery Institute 3-PHENYL-PYRAZOLO[1,5-A]PYRIMIDINE-5-CARBOXILIC ACID DERIVATIVES AS APELIN (APJ) RECEPTOR AGONISTS FOR THE TREATMENT OF CARDIOVASCULAR, METABOLIC, CNS, OR INFECTIOUS DISEASES OR DISORDERS
GB201715194D0 (en) 2017-09-20 2017-11-01 Carrick Therapeutics Ltd Compounds and their therapeutic use
CA3088347A1 (en) * 2018-01-17 2019-07-25 Glaxosmithkline Intellectual Property Development Limited Pi4kiii.beta. inhibitors
US12606561B2 (en) 2018-04-11 2026-04-21 Qurient Co., Ltd. Substituted pyrazolo[1,5-a][1,3,5]triazines as CDK inhibitors
KR20200141487A (ko) * 2018-04-11 2020-12-18 주식회사 큐리언트 사이클린 의존성 키나아제의 선택적 억제제로서의 피라졸로-트리아진 및/또는 피라졸로피리미딘 유도체
BR112020020645A2 (pt) * 2018-04-11 2021-01-12 Qurient Co., Ltd. Derivados farmaceuticamente aceitáveis de pirazol-triazina e/ou pirazol-pirimidina
US11517568B2 (en) 2018-09-12 2022-12-06 The Governing Council Of The University Of Toronto Compounds and methods for treating nematode infections
US11364234B2 (en) 2018-09-12 2022-06-21 The Governing Council Of The University Of Toronto Compounds and methods for treating nematode infections
CR20210287A (es) 2018-11-01 2022-02-15 Syros Pharmaceuticals Inc Inhibidores de cinasa 7 dependiente de ciclina (cdk7)
EP3885347B1 (en) 2018-11-14 2023-11-22 UBE Corporation Dihydropyrrolopyrazole derivative
CN110101703B (zh) * 2019-05-06 2021-06-11 暨南大学 Cdk7抑制剂在制备溃疡性结肠炎或结肠癌药物的应用
RU2713152C1 (ru) * 2019-08-30 2020-02-04 Федеральное государственное бюджетное образовательное учреждение высшего образования "Алтайский государственный медицинский университет" Министерства здравоохранения Российской Федерации Способ лечения хронической аллергической крапивницы на фоне описторхоза
TW202146416A (zh) * 2019-12-11 2021-12-16 德商拜耳廠股份有限公司 吡唑并三𠯤
GB201918541D0 (en) 2019-12-16 2020-01-29 Carrick Therapeutics Ltd Therapeutic compounds and their use
CN110950871B (zh) * 2019-12-25 2022-05-17 陕西师范大学 2-取代-4-芳氨基吡唑并三嗪衍生物及制备抗肿瘤药物的应用
CN116964061A (zh) * 2020-12-21 2023-10-27 詹森药业有限公司 作为细胞周期蛋白依赖性激酶7(cdk7)抑制剂的三环嘧啶
US20250281495A1 (en) * 2021-02-25 2025-09-11 Icahn School Of Medicine At Mount Sinai Methods for inhibiting inflammation and progression of atherosclerotic plaques and cardiovascular events in patients with cerebro- and cardio-vascular disease
CN116940577A (zh) * 2021-03-09 2023-10-24 詹森药业有限公司 作为细胞周期蛋白依赖性激酶7(cdk7)抑制剂的三环吡啶
US20250042903A1 (en) * 2021-06-17 2025-02-06 H. Lee Moffitt Cancer Center And Research Institute, Inc. Triazine inhibitors of cyclin-dependent kinases
WO2023001061A1 (en) * 2021-07-17 2023-01-26 Jingrui Biopharma Co., Ltd. Cdk7 selective inhibitors as anticancer agents
EP4377312A1 (en) 2021-07-29 2024-06-05 Syngenta Crop Protection AG Pesticidally active fused bicyclic heteroaromatic compounds
US20250019382A1 (en) * 2021-11-23 2025-01-16 Origenis Gmbh Novel inhibitors of cyclin-dependent kinases
CN114181217B (zh) * 2022-01-10 2022-12-27 陕西师范大学 吡唑并[1,5-a][1,3,5]三嗪衍生物及其盐和在制备抗癌药物中的应用
EP4493193A1 (en) * 2022-03-18 2025-01-22 Qurient Co., Ltd. Cdk7 inhibitors for antiviral treatment
CN120712267A (zh) * 2023-02-21 2025-09-26 杭州德睿智药科技有限公司 作为CDKs抑制剂的新型并杂环类新化合物及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US615968A (en) 1898-12-13 Apparatus for treating ores
HK1044334A1 (zh) * 1999-02-01 2002-10-18 Cv治疗公司 依赖细胞周期蛋白的激酶2和IκB-α的嘌呤抑制剂
US7119200B2 (en) * 2002-09-04 2006-10-10 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
AR047969A1 (es) * 2004-02-25 2006-03-15 Schering Corp Pirazolotriazinas como inhibidores de quinasa
CZ302122B6 (cs) * 2009-01-28 2010-10-20 Univerzita Palackého v Olomouci Substituované deriváty 6-(2-aminobenzylamino)purinu, jejich použití jako léciva a prípravky tyto slouceniny obsahující
FR2943058B1 (fr) * 2009-03-11 2011-06-03 Centre Nat Rech Scient Derives de pyrazolo°1,5-a!-1,3,5-triazines, leur preparation et leur application en therapeutique.
CZ302711B6 (cs) * 2009-06-03 2011-09-14 Univerzita Palackého v Olomouci Substituované deriváty 6-(2-hydroxybenzylamino)purinu, jejich použití jako léciva a farmaceutické prípravky tyto slouceniny obsahující

Also Published As

Publication number Publication date
CA2865946C (en) 2020-01-21
HUE029264T2 (en) 2017-02-28
CN104350054A (zh) 2015-02-11
ZA201406078B (en) 2016-08-31
EP2820020A1 (en) 2015-01-07
US20150018329A1 (en) 2015-01-15
MX2014010494A (es) 2015-04-08
EP2820020B1 (en) 2016-04-06
KR101821452B1 (ko) 2018-01-23
SG11201405129RA (en) 2014-09-26
CN104350054B (zh) 2017-06-13
EP2634190A1 (en) 2013-09-04
JP6182549B2 (ja) 2017-08-16
CA2865946A1 (en) 2013-09-06
IL234183A (en) 2016-11-30
BR112014021189B1 (pt) 2022-08-16
KR20140131994A (ko) 2014-11-14
DK2820020T3 (en) 2016-07-04
RU2014139705A (ru) 2016-04-20
WO2013128028A8 (en) 2014-10-02
AU2013224848B2 (en) 2017-06-29
BR112014021189A2 (enExample) 2017-06-20
ES2583231T3 (es) 2016-09-19
JP2015511952A (ja) 2015-04-23
AU2013224848A1 (en) 2014-08-28
US9567345B2 (en) 2017-02-14
HK1206014A1 (en) 2015-12-31
WO2013128028A1 (en) 2013-09-06
RU2645347C2 (ru) 2018-02-21

Similar Documents

Publication Publication Date Title
MX347359B (es) Derivados de pirazolo-triazina como inhibidores selectivos de cinasas dependientes de ciclina.
MX2012010966A (es) Derivados de triazina disustituidos farmaceuticamente activos.
AR131260A2 (es) Compuestos para tratar atrofia muscular espinal
MX2015010858A (es) Formas solidas de un inhbidor de cdk4/6 selectivo.
PH12020551639A1 (en) Pyrazolo-triazine and/or pyrazolo-pyrimidine derivatives as selective inhibitor of cyclin dependent kinase
NZ751418A (en) Crystalline form of (s)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
MX375353B (es) Compuesto de 7-(tiazol-5-il)pirrolopirimidina como agonista de tlr7
GB201205669D0 (en) Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof
GEP20156417B (en) Pyrrolo [2,3-d] pyrimidine derivatives as inhibitors of tropomyosin-related kinases
PH12020551638A1 (en) Pharmaceutically active pyrazolo-triazine and/or pyrazolo-pyrimidine derivatives
MD4735B1 (ro) Derivaţi ai pirolo[2,3-d]pirimidinei ca inhibitori de Kinaze Janus-asociate (JAK)
CL2013002177A1 (es) Compuestos derivados de 9h-purinas y 7h-pirrolo[2,3-d]-pirimidinas sustituidas, inhibidores de la pi3k de clase i y/o mtor; su composicon farmaceutica; su combinacion farmaceutica; y su uso en el tratamiento o la prevencion del cancer o trastornos neurodegenerativos.
EA201792057A1 (ru) Конденсированные бициклические гетероарильные производные с активностью ингибиторов пролилгидроксилазы
MY177365A (en) Alkyl derivatives of 1-oxa-4,9-diazaspiro undecane compounds having multimodal activity against pain
MX2015014025A (es) Derivados de n-(2,3-dihidro-1h-pirrolo[2,3,b]piridin-5-il)-4-quina zolinamina y n-(2,3-dihidro-1h-indol-5-il)-4-quinazolinamina novedosos como inhibidores de perk.
IL268923A (en) History of alicyclic-converted pyrazolo[5,1-a]pyrimidine pharmacological activity
ZA201604415B (en) [1,2,4]triazolo[1,5-a]pyrimidine derivatives as protozoan proteasome inhibitors for the treatment of parasitic diseases such as leishmaniasis
EA201790179A1 (ru) [1,2,4]триазоло[4,3-b]пиридазины для применения в лечении пролиферативных заболеваний
MX2015011588A (es) Tratamiento de combinacion.
TN2016000557A1 (en) Pharmaceutical dosage forms
BR112015025033A2 (pt) prodrogas de inibidores da pde-5 do tipo pirimidina bicíclico substituídas
EA201500366A1 (ru) Применение 1-адамантилетилокси-3-морфолино-2-пропанола или его фармацевтически приемлемых солей в фармацевтических композициях в качестве нейроретинопротектора

Legal Events

Date Code Title Description
FG Grant or registration